Kyle Doherty

Articles

Pursuit of Effective Agents Continues in Multiple Types of Sarcomas

November 10th 2023

Research has continued to focus on developing novel therapies and bringing new treatments to the sarcoma treatment paradigm.

Recent Clinical Trial Updates Shift DLBCL Treatment Paradigm

November 9th 2023

Gilles Salles, MD, PhD, expands on how data from recent clinical trials have helped shift the treatment paradigm for patients with diffuse large B-cell lymphoma.

STEAP1 Offers Potential Multifunctional Target in Prostate Cancer

November 8th 2023

Because STEAP1 is often overexpressed in prostate cancer, a disease that still largely lacks safe and effective treatment options, investigators are using it as the basis for developing novel therapies.

Recent Developments in Ovarian and Endometrial Cancers Stir Excitement Among Clinicians

November 7th 2023

Despite advanced ovarian and endometrial cancer still being accompanied by a poor prognosis and remaining largely difficult-to-treat diseases, optimism among clinicians has steadily ramped up in recent years with the development of multiple new promising agents and treatment regimens.

ASCO Recommends Trilaciclib in Extensive-Stage Small Cell Lung Cancer in Guideline Update

November 6th 2023

In their updated guidelines for patients with small cell lung cancer (SCLC), ASCO has recommended the CDK4/6 inhibitor trilaciclib as a myeloid supportive agent for patients with untreated or previously treated extensive-stage SCLC who are receiving chemotherapy or chemoimmunotherapy.

Successful Bladder Cancer Programs Rely on Old Pillars, New Innovations

November 2nd 2023

Building a successful bladder cancer program requires clinicians to employ a multifaceted approach that prioritizes good surgical practices, embraces immunotherapies with an understanding of the adverse effects that can accompany them, and being up to date in terms of options for patients.

AON Goes Public, Aims to Leverage Increased Resources Into Improved Patient Care

November 1st 2023

On September 20, 2023, with the goal of improving care, the American Oncology Network announced the completion of its business combination with Digital Transformation Opportunities Corp to become a publicly traded entity.

Maintenance Ibrutinib Leads to High PFS, OS Rates in MCL After Frontline Induction Therapy

October 27th 2023

Maintenance ibrutinib following frontline induction therapy was proven to be effective in patients with treatment-naïve mantle cell lymphoma , according to findings from a phase 2 trial published in Blood Advances.

Early Trials of PRMT5 Inhibitors Leave Much to Be Desired, But Optimism Remains

October 27th 2023

Despite the discovery of protein arginine methyltransferase 5 more than 20 years ago, interest in the potential oncogene as a treatment target for patients with hematologic and solid malignancies has increased in recent years with the advancement of multiple novel agents through preclinical and early-phase studies.

ARX517 Demonstrates Early Efficacy With Favorable Safety in Heavily Pretreated mCRPC

October 25th 2023

ARX517 displayed preliminary efficacy and a strong safety profile in patients with metastatic castration-resistant prostate cancer, according to findings from the phase 1/2 APEX-01 study.

Retrospective Data Show Nephrectomy With Immune-Targeted Therapy Offers Potential PFS Benefit in Metastatic RCC

October 24th 2023

Nephrectomy with immune-targeted therapy was associated with a progression-free survival benefit compared with immunotherapy alone in patients with metastatic renal cell carcinoma.

Amivantamab With or Without Lazertinib Extends PFS in EGFR+ Advanced NSCLC After Progression on Osimertinib

October 23rd 2023

Patients with EGFR-mutated advanced non–small cell lung cancer who experienced disease progression after treatment with osimertinib experienced a progression-free survival benefit with amivantamab plus chemotherapy with or without lazertinib compared with chemotherapy alone.

Cabozantinib Confers PFS Benefit in Previously Treated Advanced Neuroendocrine Tumors

October 22nd 2023

Patients with advanced neuroendocrine tumors who experienced progression following prior therapy experienced a significant improvement in terms of progression-free survival after treatment with cabozantinib compared with placebo.

Lifileucel Demonstrates Efficacy in Advanced Mucosal Melanoma Following Progression on Immune Checkpoint Inhibitors

October 21st 2023

Lifileucel demonstrated clinically meaningful activity in patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors, according to findings from a subgroup of patients in the phase 2 C-144-01 study.

Atezolizumab Plus Chemotherapy Fails to Provide Clinical Benefit in Recurrent Ovarian Cancer

October 20th 2023

Patients with recurrent ovarian cancer did not experience a statistically significant improvement in clinical outcomes such as progression-free survival and objective response rate with the addition of atezolizumab to chemotherapy and niraparib maintenance therapy.

Luminary Awards Highlight Exemplary Work of Experts in GI Cancers

October 18th 2023

OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, have announced the winners of the 2023 Luminary Award in GI cancers.

CHMP Recommends Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced/Recurrent Endometrial Cancer

October 16th 2023

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of dostarlimab plus chemotherapy for the treatment of adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

CHMP Recommends First-Line Pembrolizumab Plus Chemotherapy for PD-L1+, HER2– Advanced Gastric/GEJ Adenocarcinoma

October 13th 2023

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of adult patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.

CYT-0851 Plus Capecitabine Demonstrates Efficacy in Advanced Ovarian Cancer

October 12th 2023

The combination of the novel MCT inhibitor CYT-0851 and capecitabine displayed clinical activity and a tolerable safety profile in patients with advanced platinum-resistant ovarian cancer.

Tazemetostat Addition Aims to Bolster Efficacy of Lenalidomide Plus Rituximab in R/R Follicular Lymphoma

October 11th 2023

Although relapsed/refractory follicular lymphoma remains a difficult- to-treat disease, the emergence of anti-CD20 monoclonal antibodies in recent years has signaled progress, including the 2019 FDA approval of rituximab plus lenalidomide.